Sign in Subscribe
Class action lawsuits

Faruqi & Faruqi Investigates Centene for Securities Violations

Strategic Insights

— 1 min read

Faruqi & Faruqi, a leading national securities law firm, is investigating potential claims against Centene Corporation and reminds investors of the September 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action. The firm is looking into allegations that Centene provided false and misleading statements about its enrollment and morbidity rates, causing investors to suffer significant losses. As of July 1, 2025, Centene issued a press release withdrawing 2025 guidance due to lower-than-expected market growth across 22 states. As a result, the company's stock price plummeted from $56.65 per share to $33.78 per share on July 2, 2025, a decline of 40.4%.

Key Takeaways:

  • Faruqi & Faruqi is investigating potential claims against Centene Corporation for providing false and misleading statements about its enrollment and morbidity rates.
  • The investigation revolves around Centene's public statements between December 12, 2024, and June 30, 2025, which allegedly concealed material adverse facts about the company's financial health.
  • The complaint alleges that Centene's defendants kept making optimistic statements to investors while hiding the truth about the company's enrollment and morbidity rates.
  • The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who oversees the litigation on behalf of the putative class.
  • Any member of the putative class can move the Court to serve as lead plaintiff or choose to remain an absent class member.
  • Faruqi & Faruqi encourages anyone with information regarding Centene's conduct to contact the firm, including whistleblowers, former employees, shareholders, and others.

Statistics:

  • The market growth across 22 states, accounting for 72% of the Company's marketplace membership, was lower than expected (July 1, 2025).
  • The preliminary analysis resulted in a reduction of Centene's previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75 (July 1, 2025).
  • Centene's stock price declined from $56.65 per share to $33.78 per share on July 2, 2025, a decline of 40.4%.
  • The court-appointed lead plaintiff deadline is September 8, 2025.

Sources:

  • Faruqi & Faruqi, LLP
  • Centene Corporation (NYSE: CNC)
  • Newsfile Corp.
  • https://www.newsfilecorp.com/release/260336

Read more